| First carbapenem/β-lactamase inhibitor combination to be approved for use |
| Demonstrates excellent in vitro activity against Gram-negative clinical isolates, including KPC- and ESBL-producing Enterobacteriaceae |
| Noninferior to piperacillin/tazobactam in terms of clinical efficacy, and has generally similar tolerability |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.